Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Parsaclisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1426698-88-5, Incb050465, Parsaclisib [inn], Parsaclisib [usan], Incb-050465, Os7097575k
    Molecular Formula
    C20H22ClFN6O2
    Molecular Weight
    432.9  g/mol
    InChI Key
    ZQPDJCIXJHUERQ-QWRGUYRKSA-N
    FDA UNII
    OS7097575K
    Parsaclisib is an inhibitor of the delta isoform of phosphoinositide-3 kinase (PI3K) with potential antineoplastic activity. Parsaclisib inhibits the delta isoform of PI3K and prevents the activation of the PI3K/AKT signaling pathway. This both decreases proliferation and induces cell death in PI3K-delta-overexpressing tumor cells. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic disease and cell lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells. PI3K, an enzyme often overexpressed in cancer cells, plays a crucial role in tumor cell regulation and survival.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one
    2.1.2 InChI
    InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1
    2.1.3 InChI Key
    ZQPDJCIXJHUERQ-QWRGUYRKSA-N
    2.1.4 Canonical SMILES
    CCOC1=C(C(=C(C=C1C(C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)C4CC(=O)NC4
    2.1.5 Isomeric SMILES
    CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4
    2.2 Other Identifiers
    2.2.1 UNII
    OS7097575K
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. (4r)-4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

    2. 2-pyrrolidinone, 4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4r)-

    3. Incb050465

    2.3.2 Depositor-Supplied Synonyms

    1. 1426698-88-5

    2. Incb050465

    3. Parsaclisib [inn]

    4. Parsaclisib [usan]

    5. Incb-050465

    6. Os7097575k

    7. (4r)-4-[3-[(1s)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one

    8. (4r)-4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

    9. 2-pyrrolidinone, 4-(3-((1s)-1-(4-amino-3-methyl-1h-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)-, (4r)-

    10. Parsaclisib (usan/inn)

    11. Parsaclisib [usan:inn]

    12. Incb050465 Free Base

    13. Parsaclisib [who-dd]

    14. Incb-050465 Free Base

    15. Parsaclisib (incb050465)

    16. Chembl4297615

    17. Schembl14736228

    18. Unii-os7097575k

    19. Bdbm272573

    20. Ex-a2638

    21. Who 10589

    22. Db14867

    23. Ac-36916

    24. Us10065963, 32c

    25. Hy-109068

    26. Cs-0033435

    27. D11437

    28. (r)-4-(3-((s)-1-(4-amino-3-methyl-1h-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-5-chloro-2-ethoxy-6-fluorophenyl)pyrrolidin-2-one

    2.4 Create Date
    2015-02-02
    3 Chemical and Physical Properties
    Molecular Weight 432.9 g/mol
    Molecular Formula C20H22ClFN6O2
    XLogP32.4
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count5
    Exact Mass432.1476798 g/mol
    Monoisotopic Mass432.1476798 g/mol
    Topological Polar Surface Area108 Ų
    Heavy Atom Count30
    Formal Charge0
    Complexity632
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of mature B-cell malignancies